A prognostic index for advanced-stage extranodal natural killer/T-cell lymphoma: A multicenter study
Annals of Hematology · 2025
DOI: 10.1007/s00277-024-06160-6 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, 2025. Verfasst von Xiaojie Fang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine, Sun Yat-S…. Hauptthemen laut MEDLINE: Lymphoma, Extranodal NK-T-Cell. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Outstanding Young Scientific and Technological Talents Fund of Sichuan Province.
Abstract (Originalsprache)
Advanced-stage extranodal natural killer/T-cell lymphoma (ENKTL) is a highly heterogeneous disease with very poor prognosis. All commonly utilized prognostic models incorporated both early-stage and advanced-stage patients in the modeling process. This study aim to design a prognostic model specifically for advanced-stage ENKTL, providing risk stratification in affected patients. We analyzed 291 patients with stage III/IV ENKTL receiving asparaginase-based chemotherapy from 8 institutions to develop a new prognostic model and validate it in an independent cohort consisted of 221 patients from 4 additional hospitals. The prognostic model included three independent variables based on a multivariate analysis for overall survival (OS): age, bone marrow invasiveness and visceral organ involvement. We identified three different risk groups: group 1, no adverse factors; group 2, one factor; and group 3, two or three factors, which were associated with 5-year OS rates of 66.0%, 32.3%, and 20.0%, respectively (P < 0.001). The prognostic index of natural killer lymphoma (PINK) and nomogram-revised risk index (NRI) were unsatisfactory for stratifying these patients. These results were validated and confirmed in an independent cohort. This newly proposed model can be used to guide risk-adapted treatment for advanced stage ENKTL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
- Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, C…
- Department of Medical Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- Department of Medical Oncology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.
- Department of Medical Oncology, He Nan Cancer Hospital, Zhengzhou, China.
- Department of Medical Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Förderung
- National Natural Science Foundation of China
- Outstanding Young Scientific and Technological Talents Fund of Sichuan Province
Zitieren
APA
Fang, X., Zhou, F., Ye, S., Zhang, H., Guo, H., Chen, X., Liang, C., Pu, X., Cao, Y., Ren, Q., Li, X., Zhai, L., Huang, H., & Hong, H. (2025). A prognostic index for advanced-stage extranodal natural killer/T-cell lymphoma: A multicenter study. Annals of Hematology. https://doi.org/10.1007/s00277-024-06160-6
Vancouver
Fang X, Zhou F, Ye S, Zhang H, Guo H, Chen X, et al. A prognostic index for advanced-stage extranodal natural killer/T-cell lymphoma: A multicenter study. Annals of Hematology. 2025. doi:10.1007/s00277-024-06160-6
BibTeX
@article{Fang2025,
author = {Fang, Xiaojie and Zhou, Fenglan and Ye, Sheng and Zhang, Hongyu and Guo, Hongqiang and Chen, Xinggui and Liang, Chaoyong and Pu, Xingxiang and Cao, Yabing and Ren, Quanguang and Li, Xiaoqian and Zhai, Linzhu and Huang, He and Hong, Huangming},
title = {A prognostic index for advanced-stage extranodal natural killer/T-cell lymphoma: A multicenter study},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-024-06160-6}
}
EUVIMED